Intervention to Enhance PrEP Persistence

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorBrown University

About this trial

The investigators will conduct a fully powered randomized controlled trial (RCT) to test the effect of a patient navigation intervention for Black/African American (B/AA) men who have sex with men (MSM) on PrEP initiation, adherence and retention in care. B/AA men who have sex with men (MSM) are disproportionately impacted by the HIV/AIDS epidemic in the United States. Pre-exposure prophylaxis (PrEP), a once daily medication, can dramatically reduce HIV acquisition risk. However, social and structural barriers have contributed to suboptimal PrEP initiation, adherence, and retention in care among B/AA MSM. Our prior NIH-funded pilot study (R34MH109371; MPI: Nunn, Chan, Mena) developed and evaluated an Intervention to Retain and Adhere MSM in PrEP (RAMP-IT-UP), a brief strengths-based patient navigation program to enhance PrEP care outcomes among young B/AA MSM. The intervention was found to be highly acceptable among B/AA MSM and demonstrated preliminary effectiveness. Compared to control participants, RAMP-IT-UP participants were statistically more likely to initiate PrEP and adhere to PrEP based on pharmacy fill data and PrEP blood levels. Additionally, RAMP-IT-UP participants were more likely to be retained in PrEP care at the 3-month and 6-month clinical visits. Specific Aim #1 of this study will conduct a fully powered randomized controlled trial (RCT to estimate the effectiveness of RAMP-IT-UP in improving PrEP adherence and care outcomes among B/AA MSM in real-world community health center settings (CHCs). Specific Aim #2 will estimate the cost-effectiveness of RAMP-IT-UP among B/AA MSM attending CHCs compared to standard of care. The investigators will also determine the cost-effectiveness of differing levels of intensity of navigation services to prevent HIV based on data collected in Specific Aim #1. Our goal is to develop a cost-effective intervention that enhances PrEP care outcomes and reduces HIV incidence for B/AA MSM which will be relevant for CHCs across the US. The long-term goal of this work is to decrease HIV incidence among B/AA MSM, which aligns with federal Ending the HIV Epidemic and National HIV/AIDS Strategy goals. This application is led by an experienced team of investigators with a proven track record conducting HIV, PrEP and disparities research in real-world clinical settings.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Aged 18 years and older

Assigned male sex at birth

Identify as Black/African American

Report at least one male sex partner in the past 12 months

Disqualifiers

Under the age of 18

Assigned female sex at birth

Does not identify as Black/African American

Has not had a male sex partner in the past 12 months

Trial design

Design model

Parallel

Treatments tested in this trial

  • RAMP-It-Up Initiation, Adherence, and Retention Intervention

    Behavioral

    The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills

Treatment groups

300 Participants
are divided into 2 treatment groups
Group A: Standard of Care (Control Arm)No intervention 0 interventions
Group B: RAMP-It-Up interventionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

PrEP Adherence - Pharmacy Fill Data

The primary outcome will be PrEP adherence, given adherence is the definitive marker associated with protection from HIV infection. Adherence will be measured using pharmacy fill data in order to determine whether participants have picked up their prescription on a monthly basis.

Time frame
3 and 12 Month Follow Ups
2

PrEP Adherence - Drug Levels

The primary outcome will be PrEP adherence, given adherence is the definitive marker associated with protection from HIV infection. Adherence will be assessed by dried blood spot sampling for PrEP drug levels.

Time frame
3 and 12 Month Follow Ups

Secondary outcomes

1

PrEP Initiation

PrEP initiation will be measured as a secondary outcomes. This will be assessed by whether participants successfully obtained a PrEP prescription.

Time frame
3 and 12 Month Follow Ups
2

PrEP Retention in Care

PrEP retention in care will be measured as a secondary outcome. Retention in care will be quantified by the number of PrEP clinical visits attended or missed in the 12 months after initiation.

Time frame
3 and 12 Month Follow Ups

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Brown University

Lead sponsor

Whitman-Walker Institute

Collaborator

Rhode Island Public Health Institute

Collaborator

University of Mississippi Medical Center

Collaborator

National Institute of Mental Health (NIMH)

Collaborator